Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Semin Oncol. 2012 Aug;39(4):486-92. doi: 10.1053/j.seminoncol.2012.05.005.
In vivo tumor progression requires the supply of oxygen and nutrition by neovasculature. Hepatocellular carcinoma (HCC) is one of the typical tumors with neovascularization, and the dramatic alteration in the arterial vascularity may lead to acquisition of the potential for vascular invasiveness and metastasis. In 2008, phase III clinical trials revealed anti-angiogenic agent "sorafenib" as the first drug that demonstrated an improved overall survival in patients with advanced HCC. A new era of HCC treatment had arrived, but there has been limited further improvement in survival benefits. This review summarizes molecular targeted therapy with a focus on angiogenesis, growth signals, and mitotic abnormalities, as well as the promising concepts of "cancer stemness" and "synthetic lethality" for the strategy of targeted therapy.
在体肿瘤的进展需要新生血管提供氧气和营养。肝细胞癌（HCC）是具有新生血管的典型肿瘤之一，动脉血管的剧烈改变可能导致获得血管侵袭性和转移的潜力。2008 年，III 期临床试验显示，抗血管生成药物“索拉非尼”是首个能改善晚期 HCC 患者总生存期的药物。HCC 治疗的新时代已经到来，但在生存获益方面的进一步改善有限。本文综述了以血管生成、生长信号和有丝分裂异常为靶点的分子靶向治疗，以及“癌症干性”和“合成致死性”等有前途的概念，为靶向治疗策略提供了参考。
